All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Selegiline transdermal system in major depressive disorder

Author(s): Ashwin A Patkar, Kimberly B Portland,Chi-Un Pae

Selegiline transdermal system (STS) has been approved to treat major depressive disorder in the USA. STS represents a novel generation of monoamine oxidase inhibitors with a superior safety profile to older monoamine oxidase inhibitors, in particular with regard to food interactions. The efficacy and safety of STS has been established in shortand long-term clinical trials. STS expands the range of pharmacological treatment options available to clinicians to treat major depressive disorder, in particular major depressive disorder with atypical features or treatment-resistant depression. This article discusses the mechanism of action of STS, summarizes efficacy and safety data from clinical trials, reviews drug and food interactions with STS and offers suggestions for use of STS in clinical practice.


Share this       
izmir escort bayan izmir rus escort bursa escort bayan rus escort izmir escort porno indir porno izle mobil porno eskişehir escort burdur escort bartın escort havalandırma türk takipçi satın al izmir escort bursa escort türk porno escort bayan

paper io